Zoetis Inc.
Zoetis Announces Board Changes and Shareholder Proposal Results
Summary
On May 21, 2025, Zoetis Inc. announced that Mr. Robert Scully retired from the Board of Directors prior to the company's Annual Meeting, and Dr. Mark Stetter was elected to the Board. At the Annual Meeting, shareholders voted on four proposals: electing twelve directors, a non-binding advisory vote on executive compensation, ratifying the appointment of KPMG LLP as the independent registered public accounting firm, and a shareholder proposal regarding a special shareholder meeting improvement. All twelve directors were elected, the executive compensation program was approved, the appointment of KPMG LLP was ratified, and the shareholder proposal was not approved.
Profitelligence Alerts
Get alerts for ZTS
Be first to know when Zoetis Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Official SEC Documents
Advertisement